Login to Your Account

Foundation Medicine Brings in $42.5M for Genetic Cancer Test

By Randy Osborne
BioWorld Today Contributing Writer

Thursday, September 20, 2012
Foundation Medicine Inc.'s $42.5 million in a Series B financing will let the company broaden use of its marketed genetic test for mutations key to cancer therapies and, next year, expand marketing from solid tumors to hematological disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription